Background. Restenosis after percutaneous transluminal coronary angioplasty is associated with activation of medial smooth muscle cells (SMCs); they proliferate, migrate to the subintima, and narrow the vessel lumen. Cancer cells often express more cell surface receptors than do normal cells. This has allowed tumor cells to be specifically targeted using cytotoxic agents. We have examined whether a similar concept can be applied to rapidly proliferating but nontransformed SMCs. Pseudomonas exotoxin (PE; MW, 66 kDa) is a potent toxin that kills cells by inhibiting protein synthesis; its toxicity is diminished when its cell recognition domain is deleted to produce a 40-kDa protein (PE40).
Methods and Results. A complementary DNA encoding transforming growth factor a (TGFa) was ligated to that encoding PE40 and the chimeric toxin TGFcY-PE40, which is cytotoxic to cancer cells displaying epidermal growth factor (EGF) receptors, was expressed in Escherichia coli. The ability of this toxin to kill proliferating SMCs was tested. When cells were seeded at low density (2,500 cells/cm2) and grown in medium supplemented with 10% fetal bovine serum, they were found to be rapidly proliferating; these cells were very sensitive to the cytotoxic effects of TGFa-PE40 (ID50, 4 .0±0.17 ng/ml). In contrast, cytotoxicity was 30-fold less (ID50, 125+±23 ng/ml; p<0.0004) when cells were in a quiescent state (grown in medium supplemented with 0.5% fetal bovine serum).
Conclusions. Competition studies using excess EGF indicated that the cytotoxic effects of TGFa-PE40 are specifically mediated by the EGF receptor. EGF receptor binding analysis demonstrated that rapidly proliferating SMCs display 10-fold more EGF receptors than do quiescent SMCs in vitro. Thus, a chimeric toxin targeted toward the EGF receptor can selectively kill rapidly proliferating SMCs. Whether this toxin or other chimeric toxins directed against other cell surface receptors will effectively inhibit SMCs proliferating in vivo or be useful in preventing restenosis remains to be determined. (Circulation 1991; 84:778-787) Pe ercutaneous transluminal coronary angioplasty (PTCA) has become a critically important modality in the treatment of coronary artery disease. However, although the initial success rate of PTCA for opening narrowed coronary vessels is very high, late restenosis occurs in 25-50% of patients. [1] [2] [3] [4] [5] This complication has proven refractory to a diverse the development of highly specific targeted therapy. This strategy is based on a hypothesis derived from newer innovative therapeutic approaches to treating cancer, which take advantage of the fact that cancer cells often express high levels of receptors that are usually either absent or present at a low density. '1-14 This characteristic of certain transformed cells stimulated the development of cytotoxic agents specifically targeted to the cancer cells that overexpress these receptors. [15] [16] [17] [18] [19] [20] We speculated that because activated smooth muscle cells also express higher numbers of certain cell surface receptors than do nonactivated cells, their excessive growth might be controlled by an analogous therapeutic approach.
One group of cytotoxic molecules that has been designed by recombinant DNA techniques to target certain cancer cells is derived from genetically modified Pseudomonas exotoxin A (PE). PE is one of a class of ADP-ribosyl transferases that includes diphtheria toxin, Escherichia coli enterotoxin, and cholera toxin. PE binds to its cell surface receptor, is internalized by coated pits into endocytic vesicles, and is then translocated into the cell cytoplasm. 21 Figure 1 . A mutated form of TGFa-PE40, TGFa-PE40asP (which contains no ADP-ribosylation activity and serves as a control for toxin-mediated cytotoxicity), was constructed by ligating the 0.45 -kb BamHI-EcoRI fragment (encompassing the Asp553 mutation) derived from a previously described ADP-ribosylation mutant interleukin 6 (IL-6)-PE40asP553, with the 3.5-kb BamHI-EcoRI DNA fragment derived from TGFa-PE40. 30 
Expression of Recombinant Protein
To express the chimeric protein TGFa-PE40, E. coli BL21 (ADE3) cells that were transformed with the plasmid carrying the gene fusion (TGFa-PE40) were cultured to OD650 of 1.0 and induced for 90 minutes with 1 mM isopropyl-thiogalactoside. The total cell pellet was fractionated, and inclusion bodies, which contained the fusion protein, were isolated from the spheroplast fraction. The details of these procedures have been previously described. 20 Purification of Recombinant Protein TGFa-PE40 was found mainly in insoluble form located in the inclusion bodies. The fusion protein was denatured in guanidine-HCl and renatured by rapid dilution in phosphate-buffered saline. Purification was performed by anion-exchange chromatography (Mono Q, Pharmacia) followed by gel filtration using a TSK-250 column. Fractions containing ADPribosylation and cell-killing activity were used for subsequent experiments. 20 Other Toxins and Toxin Mutants Native PE was expressed in a fashion similar to that outlined for TGFa-PE40 and purified from the periplasm fraction of E. coli.31 TGFa-PE40asP553, which has a single amino acid mutation at residue 553 (Glu to Asp), was also expressed and purified in the same way as TGFa-PE40. This mutation eliminates the ADP-ribosylation capacity of [3H]Leucine was obtained from Amersham Corp., Arlington Heights, Ill. Six dose-response curves, each determined in duplicate, were performed using rat aortic smooth muscle cells (passages 16 and 17) , and five dose-response curves were performed in duplicate using rabbit aortic smooth muscle cells (passages 5 and 6).
Competition Assay
Competition assays were performed by the addition of an excess of recombinant EGF. TGFa-PE40 was added to the smooth muscle cells 24 hours after seeding in either the presence or absence of excess EGF (500 ng/ml). Cells were seeded at a density of 2,500 cells/cm2 and grown in medium supplemented with 10% FBS. After a 48-hour incubation period at 37°C, protein synthesis was estimated by the [3H]leucine incorporation assay. For these experiments, cell passage numbers of the smooth muscle cells derived from rat and rabbit aortas were 17 and 5, respectively. Cell Counting TGFa-PE40 was found to inhibit leucine uptake of cells grown in 10% FBS. To determine whether the decrease in leucine uptake caused by TGFa-PE40 in 10% FBS reflected a direct effect of TGFa-PE40 on cell viability, the absolute numbers of cells were counted in an additional experiment. Four days after seeding rat aortic smooth muscle cells (2,500 cells/ cm2; passage 2), TGFa-PE40 was added. At the end of a 96-hour incubation with the chimeric toxin, cells were counted manually using a hemocytometer.
PE was found to inhibit leucine uptake in both 10% and 0.5% FBS. The question arose as to whether the decreased leucine uptake of quiescent cells (those grown in 0.5% FBS) reflects decreased cell viability or whether decreased protein synthesis in such cells could occur and not lead to cell death. Therefore, in another experiment, which was performed in triplicate, absolute numbers of cells were counted to assess the direct effect of PE on cell viability in 0.5% FBS. Rat aortic smooth muscle cells (50,000 cells/cm2; passage 9) were used; the protocol was like that of the TGFa-PE40 cell-counting experiment, except that cells were counted by Coulter counter. Thymidine Incorporation Four days after seeding rat aortic smooth muscle cells (passage 2), [3H]thymidine was added (4 ,uCi/ml, 6.7 Ci/mmol; Du Pont Co., Boston). After 
Results
Purification of TGFa-PE40
The purification procedure described in "Methods" resulted in a homogenous monomeric protein with a molecular weight of 46 kDa, visualized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and staining with Coomassie blue. Its identification as TGFa-PE40 was confirmed by immunoblot analysis using antibodies to PE (Figure 3 ).
Cytotoxic Activity
Effects of TGFa-PE40 on rapidly proliferating smooth muscle cells. Sparsely plated cells (2,500 cells/ cm2) cultured in medium containing 10% FBS were found to be proliferating at relatively rapid rates ( Figure 2 and Table 1 ). Dose-response curves depicting the inhibitory effects on [3H]leucine incorporation of TGFa-PE40 against rapidly proliferating rabbit and rat smooth muscle cells are shown in Figure 4 . Because no significant differences were found between experiments in which the cells were exposed to toxin for 48 compared with 96 hours, these data were pooled. The ID5s values of TGFa-PE40 against rabbit and rat aortic smooth muscle cells were 15 and 20 ng/ml, respectively. Direct evidence of cell-killing activity was documented by cell counting: fewer cells survived 96 hours of incubation when they were exposed to the chimeric toxin. In these experiments, the amount of TGFa-PE40 that reduced the number of living cells by 50% was 7 ng/ml ( Figure 5 ).
Comparative effects of TGFa-PE40 on rapidly proliferating versus quiescent smooth muscle cells. Culturing cells in medium with low serum concentration encouraged a quiescent state as indicated by the flat growth curve (Figure 2 ) and low tritiated thymidine incorporation ( Table 1 ). The cytotoxic effect of TGFa-PE40 on these quiescent cells was significantly lower than that observed on rapidly proliferating cells ( Figure 6) Direct evidence that the decreased leucine uptake reflected cell-killing activity, even in quiescent cells (those growing in 0.5% FBS), was documented by 1 10 TGFa-PE40 (ng/mlI) cell counting; fewer cells growing in medium supplemented with 0.5% FBS survived 96 hours of incubation when exposed to PE. In these experiments, the amount of PE that reduced the number of living cells by 50% was 0.7 ng/ml ( Figure 5 ).
Receptor Mediation of Cytotoxic Effects of TGFa-PE40
To determine whether the cytotoxic effects of TGFa-PE40 are specifically mediated by its binding to the EGF receptor, a competition assay using EGF was performed on smooth muscle cells growing in 10% FBS. Excess EGF completely blocked the inhibitory effects of TGFa-PE40 (Figure 7) , whereas EGF alone exerted no effect on leucine incorporation (data not shown). low-affinity sites was found to be 32,000. The dissociation constants were 1.7XlO-`M and 1.3xlO-9 M for the high-and low-affinity sites, respectively.
EGF Receptor Analysis of Rapidly Proliferating Versus

Specificity of Cytotoxic Effects of TGFax-PE40
To document that the cytotoxic effect of TGFa-PE40 on smooth muscle cells was a result of the chimneric protein rather than of its individual components, the effects of PE40 and of TGFa, separately and together, on smooth muscle protein synthesis were determined by using the same molar concentrations used for the chimeric protein; no cytotoxic activity was demonstrated ( Figure 9 ). To demonstrate that the cytotoxic effects of TGFa-PE40 were a result of the chimeric protein and not of a bacterial contaminant derived during protein expression (e.g., E. coli endotoxin), dose-response curves using an inactive TGFa-PE40 mutant were determined (TGFaPE40aSP553). No cytotoxic effect of this molecule on the smooth muscle cells was found despite the fact that it was cloned, expressed, and purified using methods identical to those used for TGFa-PE40 ( Figure 9 ).
Discussion
A major breakthrough in understanding the pathophysiological processes involved in restenosis after PTCA was the recognition that a critical step in the chain of events leading to restenosis is injury-induced activation of medial smooth muscle cells, which causes their proliferation and migration to the subintima6-10; if this "healing" response is excessive, it leads to luminal narrowing and restenosis.
A further key to our understanding of the restenosis process, and thereby of its treatment, was the finding that smooth muscle cells have the capacity to express, either constitutively, in response to injury, or in response to being placed in culture, growth factors and cytokines such as platelet-derived growth factor (PDGF); fibroblast growth factor, both acidic and basic forms (FGF); interleukin 1 (IL-1); interleukin 6 (IL-6); insulin-like growth factors I and II (IGF-I and IGF-II); and transforming growth factor /3 (TGFj3).32-41 Furthermore, smooth muscle cells also exhibit a mitogenic response to several of these factors, indicating that receptors for some of these ligands must be present. [17] [18] [19] [20] 48, 49 Given this background, we tested our hypothesis that a similar targeting strategy might be successful when directed to rapidly proliferating but nontransformed smooth muscle cells. To this end, we determined whether TGFa-PE40, a chimeric toxin previously found to be extremely potent in killing certain cancer cells,20 would be cytotoxic to rapidly proliferating smooth muscle cells.
Several potentially important observations derive from our investigation. First, we found that TGFa-PE40 is cytotoxic in vitro to aortic smooth muscle cells derived from rats and rabbits, exhibiting an ID50 of 4-20 ng/ml when directed against smooth muscle cells plated at low density (2,500 cells/cm2) and cultured in serum-rich media (Figures 4 and 5 ). The cells growing under these conditions have a high tritiated thymidine uptake (indicative of a high rate of DNA synthesis) and a rapid doubling time (Table  1 and Figure 2 ). The cytotoxic effects were observed with cells of early or late passage numbers. This is most easily seen by comparing Figure 4 (rat smooth muscle cells; passages 16 and 17) with Figure 6 (rat smooth muscle cells; passage 2).
TGFa has 30% amino acid homology to EGF, including the conservation of all six of EGF's cysteines. The two ligands are recognized by the binding site of the EGF receptor with practically identical affinities.50-54 This latter fact undoubtedly explains the finding that cytotoxic activity of TGFa-PE40 is lost when it is coincubated with an excess of EGF (Figure 8 ) (e.g., its cell-killing effect results from its binding to the EGF receptor).
If TGFa-PE40 killed all smooth muscle cells with which it came into contact, it would have little therapeutic potential. However, we found that the molecule had considerably less cytotoxicity against quiescent compared with rapidly proliferating smooth muscle cells ( Figure 6 ). The greater cytotoxic capacity against rapidly proliferating cells could result from any of several possible mechanisms. For example, the rapidly proliferating cells could more efficiently internalize the toxin or more efficiently translocate it from the endocytic compartment to the cytoplasm. This possibility is unlikely because there was no statistically significant difference in cytotoxicity when native Pseudomonas exotoxin was added to either rapidly proliferating or quiescent smooth muscle cells (Figure 6 ). Alternatively, the EGF receptor could be upregulated or have a higher binding affinity during the culture conditions that caused rapid cell proliferation. In this regard, cultured smooth muscle cells in the exponential phase of growth have been shown to bind more EGF than do quiescent cells. 47 Other studies have shown that cell surface receptors for several growth factors, including EGF, are fewer in number in cells grown at high density than in those grown at low density.55-59 Although these latter differences were ascribed to effects of cell density on receptor number, an effect of proliferation rate was not ruled out. Our data clearly show that rapidly proliferating smooth muscle cells express 10-fold more EGF receptors per cell (44,000 versus 4,200) than quiescent smooth muscle cells (Figure 8 ), which may result in more EGF binding and thereby account for some of the increased cytotoxicity of rapidly growing smooth muscle cells to TGFa-PE40. Our data therefore suggest that in vitro rapidly proliferating smooth muscle cells overexpress EGF receptors and a chimeric toxin can be specifically targeted to such cells. These findings may provide the basis by which smooth muscle cells that have responded to vascular injury after PTCA by rapidly proliferatingthat is, those cells destined to compromise vascular patency and cause restenosis after PTCA-can be selectively killed.
Because the gene fusion encoding TGFa-PE40 is expressed in E. coli contamination with E. coli endotoxin is inevitable. It was therefore imperative to determine that the cytotoxic effects of TGFa-PE40 result from its intrinsic activity rather than from contaminating bacterial products. That this is the case is demonstrated by several lines of evidence. First, the cytotoxic effects of TGFc-PE40 are eliminated when the chimeric toxin is coincubated with an excess of EGF (Figure 8 ), which competes with TGFa-PE40 for the EGF receptor. This effect should be specific for TGFa-PE40 and should not be seen if the cytotoxic effect were the result of a bacterial product. Second, TGFapE40asp553, a mutant of TGFa-PE40 genetically engineered to be devoid of cytotoxic activity30 that was cloned, expressed, and purified in a manner identical to that used to produce TGFa-PE40, was found to exert no cytotoxic action on smooth muscle cells ( Figure 9 ). TGFa-PE40 is just one of many possible ligandtoxin fusions that might be used to target rapidly proliferating smooth muscle cells. Preliminary results in our laboratory have shown that other ligands that have been genetically fused to PE40 (e.g., acidic FGF and 1GF-I) exert cytotoxic effects on smooth muscle cells (personal observation); so also does the agent produced by chemical conjugation of basic FGF to saporin (a potent plant toxin).60
The in vitro studies we have reported raise the intriguing possibility that use of recombinant techniques to produce "killer" molecules that selectively target actively proliferating cells might be applied to the problem of restenosis after PTCA. It remains to be seen, however, not only whether the selective cytotoxic effects achieved in vitro can be achieved in vivo but also whether they can be achieved without the complication of important deleterious actions on either the healing response to vascular injury, the vascular wall, or nonvascular cells and tissues.
